| Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/01/2023 | Kellen Scott | CFO and Secretary | Grant | Stock Option (right to buy) | 67k | $2.73 | $182.9k | | 06/01/2023 |
| 06/01/2023 | Parsons James T. | Director | Grant | Stock Option (right to buy) | 17k | $2.73 | $46.3k | | 06/01/2023 |
| 06/01/2023 | Pilnik Richard D. | Director | Grant | Stock Option (right to buy) | 22.4k | $2.73 | $61k | | 06/01/2023 |
| 06/01/2023 | Pauls Dietrich John | President and CEO | Grant | Stock option (right to buy) | 181k | $2.73 | $494.1k | | 06/01/2023 |
| 06/01/2023 | Semba Charles Pauling | Director | Grant | Stock Option (right to buy) | 17k | $2.73 | $46.3k | | 06/01/2023 |
| 06/01/2023 | Gruis Kirsten L | Chief Medical Officer | Grant | Stock Option (right to buy) | 67k | $2.73 | $182.9k | | 06/01/2023 |
| 06/01/2023 | Cundari Dominic R | Chief Commercial Officer | Grant | Stock Option (right to buy) | 27k | $2.73 | $73.7k | | 06/01/2023 |
| 06/01/2023 | Daves Julie VanOrsdel | SVP Clinical Development Oper. | Grant | Stock Option (right to buy) | 54k | $2.73 | $147.4k | | 06/01/2023 |
| 05/30/2023 | Kuntz Richard | Director | Grant | Stock option (right to buy) | 32.3k | $2.81 | $90.8k | | 05/30/2023 |
| 03/01/2023 | Lewis Tanya | Director | Grant | Stock option (right to buy) | 26.4k | $1.77 | $46.8k | | 03/01/2023 |
| 01/03/2023 | Giuffre Randall Michael | Director | Grant | Voting Common Shares, no par value per share | 35.1k | $1.53 | $53.7k | | 01/03/2023 |
| 01/03/2023 | Pilnik Richard D. | Director | Grant | Voting Common Shares, no par value per share | 55.6k | $1.53 | $85k | | 01/03/2023 |
| 01/03/2023 | Burroughs Amy L. | Director | Grant | Voting Common Shares, no par value per share | 17.2k | $1.53 | $26.2k | | 01/03/2023 |
| 01/03/2023 | Semba Charles Pauling | Director | Grant | Voting Common Shares, no par value per share | 17.2k | $1.53 | $26.2k | | 01/03/2023 |
| 12/09/2022 | Giuffre Randall Michael | Director | Purchase | Voting Common Shares, no par value per share | 37.1k | $1.43 | $53k | | 12/08/2022 |
| 12/08/2022 | Giuffre Randall Michael | Director | Purchase | Voting Common Shares, no par value per share | 20k | $1.40 | $28k | | 12/08/2022 |
| 12/07/2022 | Giuffre Randall Michael | Director | Purchase | Voting Common Shares, no par value per share | 22.6k | $1.40 | $31.6k | | 12/06/2022 |
| 12/06/2022 | Giuffre Randall Michael | Director | Purchase | Voting Common Shares, no par value per share | 2.3k | $1.35 | $3.1k | | 12/06/2022 |
| 12/05/2022 | Pilnik Richard D. | Director | Purchase | Voting Common Shares, no par value per share | 35k | $1.39 | $48.5k | | 12/05/2022 |
| 12/02/2022 | Von Koch Thomas | 10% Owner | Sale | Common Shares | 2.9M | $1.24 | $3.5M | See Footnote 1 | 12/02/2022 |
| 12/02/2022 | Von Koch Thomas | 10% Owner | Purchase | Common Shares | 2.9M | $1.24 | $3.5M | See Footnote 2 | 12/02/2022 |
| 12/01/2022 | Giuffre Randall Michael | Director | Purchase | Voting Common Shares, no par value per share | 46.1k | $1.20 | $55.4k | | 11/29/2022 |
| 12/01/2022 | Giuffre Randall Michael | Director | Purchase | Voting Common Shares, no par value per share | 819 | $1.19 | $974.6 | | 12/01/2022 |
| 11/30/2022 | Giuffre Randall Michael | Director | Purchase | Voting Common Shares, no par value per share | 3k | $1.19 | $3.5k | | 11/29/2022 |
| 11/29/2022 | Giuffre Randall Michael | Director | Purchase | Voting Common Shares, no par value per share | 18.1k | $1.19 | $21.6k | | 11/29/2022 |
| 11/16/2022 | Pauls Dietrich John | President and CEO | Purchase | Voting Common Shares, no par value per share | 20k | $1.21 | $24.2k | | 11/16/2022 |
| 09/13/2022 | Daves Julie VanOrsdel | SVP Clinical Development Oper. | Grant | Stock Option (right to buy) | 140k | $1.47 | $205.8k | | 09/13/2022 |
| 07/08/2022 | Von Koch Thomas | 10% Owner | Purchase | Common Shares | 208k | $1.33 | $275.9k | See Footnote | 07/08/2022 |
| 06/01/2022 | Burroughs Amy L. | Director | Grant | Stock Option (right to buy) | 13.2k | $2.45 | $32.4k | | 06/01/2022 |
| 06/01/2022 | Semba Charles Pauling | Director | Grant | Stock Option (right to buy) | 13.2k | $2.45 | $32.4k | | 06/01/2022 |
| 06/01/2022 | Pauls Dietrich John | President and CEO | Grant | Stock Option (right to buy) | 177k | $2.45 | $433.6k | | 06/01/2022 |
| 06/01/2022 | Pilnik Richard D. | Director | Grant | Stock Option (right to buy) | 18.5k | $2.45 | $45.3k | | 06/01/2022 |
| 06/01/2022 | Giuffre Randall Michael | Director | Grant | Stock Option (right to buy) | 13.2k | $2.45 | $32.4k | | 06/01/2022 |
| 06/01/2022 | Parsons James T. | Director | Grant | Stock Option (right to buy) | 13.2k | $2.45 | $32.4k | | 06/01/2022 |
| 06/01/2022 | Kellen Scott | CFO and Secretary | Grant | Stock Option (right to buy) | 60k | $2.45 | $147k | | 06/01/2022 |
|